Skip to main content

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cance

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cance

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 213
  • Page 214
  • Page 215
  • Page 216
  • Page 217
  • Page 218
  • Page 219
  • Page 220
  • Page 221
  • …
  • Next page Next
  • Last page Last
Subscribe to